Biohaven Pharmaceutical Holding Company Ltd. Stock

$36.66

0.66% day before yesterday

NYSE, Dec 27, 10:00 pm CET

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$36.66

-19.37 34.57% 5Y

NYSE, Closing price Fri, Dec 27 2024

+0.24 0.66%

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.71b
Enterprise Value	$3.36b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	11.01
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-848.89m
Free Cash Flow (TTM) Free Cash Flow	$-531.06m
Cash position	$379.40m
EPS (TTM) EPS	$-9.35
P/E forward	negative
Short interest	8.71%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

15x Buy

100%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	3.87 3.87	40% 40% -
Gross Profit	-3.87 -3.87	40% 40% -
- Selling and Administrative Expenses	78 78	32% 32% -
- Research and Development Expense	763 763	103% 103% -
EBITDA	-845 -845	71% 71% -
- Depreciation and Amortization	3.87 3.87	40% 40% -
EBIT (Operating Income) EBIT	-849 -849	71% 71% -
Net Profit	-804 -804	73% 73% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral

PRNewsWire

●

13 days ago

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within hours of each weekly dose administration, and pharmacodynamic effects were sustained relative to baseline over the four-week period.

Neutral

PRNewsWire

●

23 days ago

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing Phase 2 and 3 clinical studies , demonstrating excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as somnolenc...

Positive

Seeking Alpha

●

30 days ago

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor fun...

More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office	Virgin Islands, British
CEO	Vladimir Coric
Employees	239
Founded	2022
Website	www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now